1-4 of 4
John Chirgwin
Close
Sort by
Journal Articles

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

Attaya Suvannasankha, Colin D. Crean, David Halladay, David G. Roodman, John Chirgwin
Journal: Blood
Blood (2022) 140 (Supplement 1): 7104–7105.
https://doi.org/10.1182/blood-2022-171069
Published: 2022
Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4391.
https://doi.org/10.1182/blood-2019-131865
Published: 2019
Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4450.
https://doi.org/10.1182/blood-2018-99-115680
Published: 2018
Journal Articles

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Noriyoshi Kurihara, DDS, PhD, Yasuhisa Ohata, MD PhD, Gabriel M. Pagnotti, PhD, John Chirgwin, PhD, G David Roodman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4360.
https://doi.org/10.1182/blood.V130.Suppl_1.4360.4360
Published: 2017